| Aspect | Cero (YC S21) | OhMD | Luma Health (product overview and review listing) |
|--------|---------------|----------------|----------------|
| Starting Price | Not published (demo/sales-led) | Published starting monthly pricing for core plans; enterprise/custom plans available; calling usage billed separately | Not published (review listing indicates no pricing listed) |
| Recommended For | LATAM clinics/hospitals that rely heavily on WhatsApp and are seeking to reduce no-shows via automated confirmation/rescheduling/waitlists | US practices seeking HIPAA-positioned texting + AI voice/call deflection + EHR integration | Organizations seeking broader patient access/engagement workflows (exact fit depends on deployment scope) |
| Key Strength | WhatsApp-first coordination; focus on natural-language replies and operational scheduling actions | Transparent entry pricing; broader channel mix (text + voice) and explicit enterprise features (SSO etc.) | Brand presence in patient access category; (often) broader patient access scope |
| Key Weakness | Limited publicly documented security/compliance; minimal presence on mainstream review platforms; pricing opaque | Calling costs can add variability; US regulatory framing may not translate to LATAM | Pricing opaque; product naming confusion due to "Luma" brand collisions |
- Direct competitors and their key differentiators
- OhMD
- Clear published entry pricing and packaging, plus explicit mention of enterprise security/compliance features (BAA, MFA, SSO) and AI call automation.
- Klara
- Commonly evaluated against OhMD; tends to compete on patient messaging and practice workflows (Cero’s LATAM WhatsApp focus may differentiate).
- Luma Health / Phreesia / Artera
- Often broader patient access stacks (intake, scheduling, outreach), typically enterprise and custom priced.
- Emitrr
- Often competes on bundled phone + texting + scheduling reminders with third-party promotional claims that should be validated.
- Feature comparison: where does Cero excel vs lag behind?
- Potential areas of strength
- WhatsApp-native patient coordination is advantageous in LATAM where WhatsApp adoption is widespread.
- Operational actions (auto-reschedule, waitlist fill) are presented as core functionality rather than optional modules.
- Potential gaps / unknowns
- Enterprise trust artifacts (SOC 2, ISO 27001, penetration test disclosures) are not clearly published.
- Omnichannel capabilities, voice AI, and intake forms may be less prominent or not core (not confirmable from public sources).
- Pricing comparison: value proposition vs alternatives
- Cero: a usage-based "effective communication" model (per YC messaging) may align cost with activity, but forecasting may be harder than per-location or per-provider subscriptions.
- OhMD: subscription entry pricing is published, but usage-based calling fees add variability.
- Luma/Phreesia/Artera: often custom pricing; suitable for larger deployments but can increase procurement complexity.
- Customer testimonials comparing products
- No credible, direct "Cero vs X" customer quotes were found in accessible public sources.
- Market share and adoption trends
- No authoritative market share data found.
- Adoption indicators:
- Vendor claims a few hundred centers and a large monthly appointment volume.
- YC S21 profile and related accelerator materials indicate early traction and reported profitability.